The Australian has published a Special Report titled ‘LTR Pharma completes study milestone for SPONTAN ED treatment’, outlining that LTR Pharma has completed a key extractables study for its SPONTAN intranasal spray for erectile dysfunction and kicked off a leachables study as part of a regulatory development program.
“The completion of our extractables study and commencement of the leachables phase keep our regulatory program on schedule,” LTR Pharma executive chairman Lee Rodne said.